Natura-alpha targets forkhead box M1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4414-4424

  Li, Yirong ^a   Ligr, Martin ^a   McCarron, James P ^c   Daniels, Garrett ^a   Zhang, David ^d   Zhao, Xin ^d   Ye, Fei ^d   Wang, Jinhua ^a   Liu, Xiaomei ^a   Osman, Iman ^a   Mencher, Simon K ^e   Lepor, Hebert ^a   Wang, Long G ^a,e   Lee, Peng ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Natrogen Therapeutics International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; FORKHEAD BOX M1 TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR; HERBACEOUS AGENT; NATURA ALPHA; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CASE REPORT; CELL INVASION; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HERBAL MEDICINE; HORMONE ACTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

AGED, 80 AND OVER; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FATAL OUTCOME; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960319281     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0431     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
3. Spugnini EP, Campioni M, D'Avino A, Caruso G, Citro G, Baldi A. Cellcycle molecules in mesothelioma: an overview. J Exp Clin Cancer Res 2007;26:443-9.
4. Sharma PS, Sharma R, Tyagi R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 2008;8:53-75. (Pubitemid 351237910)
5. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995;1:1245-6.
6. Boxem M. Cyclin-dependent kinases in C. elegans. Cell Div 2006;1:6.
7. Lee JC, Adams JL. Inhibitors of serine/threonine kinases. Curr Opin Biotechnol 1995;6:657-61.
8. Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999;6:859-75. (Pubitemid 29422199)
9. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-67. (Pubitemid 351430863)
10. Senderowicz AM. Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif 2002;20: 169-96.
11. Godman J, Balk J. Genome analysis of Chlamydomonas reinhardtii reveals the existence of multiple, compartmentalized iron-sulfur protein assembly machineries of different evolutionary origins. Genetics 2008;179:59-68.
12. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-60. (Pubitemid 46649860)
13. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994;12:53-63. (Pubitemid 24045786)
14. Ji XJ, Liu XM, Li K, Chen RH, Wang LG. Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomed Environ Sci 1991;4:332-7.
15. Meijer LG N, Skaltsounis LA, Eisenbrand G,editors. Indirbin, the red shade of indigo in editions. Life in progress. Roscoff, France: Place Georges Teissier; 2006.
16. Wang LG, Mencher SK. Multiple faces of indirubin and its analogues in fighting cancer. Life in Progress Editions: Place Georges Teissier, Roscoff, France; 2006.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999;179:336-46. (Pubitemid 29203158)
19. Wang LG, Ossowski L, Ferrari AC. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 2001;61:7544-51. (Pubitemid 32995046)
20. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 2009;69:3332-8.
21. Liu XM, Jiang JD, Ferrari AC, Budman DR, Wang LG. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer 2003;89:1566-73. (Pubitemid 37386616)
22. Wang LG, Liu XM, Chiao JW. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 2006;27:2124-32. (Pubitemid 44530587)
23. Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A 2008;105:5236-41. (Pubitemid 351738540)
24. Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 2008;27:3201-10. (Pubitemid 351693177)
25. Taneja S, MacGregor J, Markus S, Ha S, Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 2001;98:8804-8. (Pubitemid 32678108)
26. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24. (Pubitemid 24330215)
27. Tatsuda Y, Iguchi K, Usui S, Suzui M, Hirano K. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells. Eur J Pharmacol 2010;627:348-53.
28. Willey CD, Xiao D, Tu T, Woon Kim K, Moretti L, Niermann KJ, et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 2010;77:1518-26.
29. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
30. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407. (Pubitemid 44018812)
31. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007;388:1257-74. (Pubitemid 350135573)
32. Glatigny S, Blaton MA, Mencher SK, Mistou S, Lucas B, Fournier C, et al. Treatment of collagen-induced arthritis by Natura-alpha via regulation of Th-1/Th-17 responses. Eur J Immunol 40:460-9.
33. Lee MAmerican Society of Health-System Pharmacists. Basic skills in interpreting laboratory data. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2009.
34. Leibovici D, Lindner A, Stay K, Zisman A. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance]. Harefuah 2006;145:763-7, 780, 781.
35. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA. Complex cadherin expression in human prostate cancer cells. Int J Cancer 2000;85:446-50. (Pubitemid 30030421)
36. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, et al. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 1999;274:9656-64.
37. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. Am J Pathol 1999;155:787-98. (Pubitemid 29426824)
38. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg Oncol 2006;15:117-28. (Pubitemid 46241866)
39. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42. (Pubitemid 38812466)
40. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
41. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28. (Pubitemid 37315193)
42. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007;7:847-59. (Pubitemid 350006253)
43. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-36. (Pubitemid 40268127)
44. Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation- dependent recruitment of p300/CBP coactivators. Mol Cell Biol 2004;24:2649-61. (Pubitemid 38381258)
45. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 2006;66:9731-5. (Pubitemid 44623674)
46. Gartel AL. FoxM1 inhibitors as potential anticancer drugs. Expert Opin Ther Targets 2008;12:663-5. (Pubitemid 351877295)
47. McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 2009;8:582-91.